LOT NO. 001NDC 6829-0001-01 ·  MAYCAUSEGROWTH.COMRx ONLY
Boxed WarningRead before use

Warning:
May Cause
Growth.

A boutique growth agency for telehealth clinics, peptide therapy, and supplement brands. Administered via paid acquisition and ad creative. Not available over the counter.

Apply for TreatmentIntake closes when capacity is reached
Keep out of reach of competitors
Growth marketing (oral)  ·  30 sessions
6 82900 000011 4
SIDE EFFECTS MAY INCLUDE: INCREASED PATIENT VOLUME • FULLY BOOKED PROVIDERS • ELEVATED ROAS • COMPOUNDING RETURNS • WAITLISTS • PHARMACY SUPPLY ISSUES • STAFF SHORTAGES DUE TO DEMAND • DIFFICULTY REMEMBERING LIFE BEFORE US •
§ 01Indications & UsageWHO THIS IS FOR
Drug Facts
Indicated for the treatment of
Slow patient acquisition — TRT clinicsPrimary
GLP-1 & medical weight lossPrimary
Longevity & peptide therapyPrimary
Stagnant growth in supplement brandsPrimary
Not indicated for
Brands seeking the cheapest option.
Clinics allergic to spending money to make money.
Anyone who wants it done slowly.
Prescriber’s note

We work with operators who already have a real offer, a licensed prescriber in the states they advertise into, and the capacity to answer the phone. Everything after that is our problem.

If your funnel isn’t ready, we say so during intake — before you spend a dollar with us.

Take as directed
§ 02Active IngredientsPER ENGAGEMENT

Paid Patient Acquisition

Meta, Google, TikTok. Campaigns engineered for cost-per-booked-consult, not vanity metrics.

500mg

Ad Creative Production

Direct-response creative that stops the scroll and survives compliance review. Hooks, scripts, statics, UGC direction.

500mg
Inactive ingredients: none. We don’t pad retainers with filler.1000mg total
§ 03Mechanism of ActionHOW IT WORKS
Phase I
01

Intake

We audit your funnel, offer, and unit economics before a dollar is spent. If we can’t grow you, we tell you and refer you out.

Phase II
02

Loading Dose

An aggressive first 60 days: creative testing at volume, rapid kill/scale decisions, weekly readouts in plain English.

Phase III
03

Maintenance Dose

Winners scaled, losers cut, new creative shipped continuously. Growth becomes chronic.

§ 04Clinical ResultsCONFIDENTIAL
Clinical Results — ConfidentialRedacted per MSA §7.2
CASE 01 — TRT CLINIC,
Booked consults per month: → in 90 days.
Return on ad spend: 3.2x sustained.
Cost per acquisition: -41% CPA against prior agency.
CASE 02 — GLP-1 PROGRAM. Provider capacity reached; intake moved to a waitlist at week .
CASE 03 — PEPTIDE BRAND. Subscription retention at month six: .
Prior agency of record: . Current status: .
Unsealed during consultation only

Our clients compete in small, aggressive markets. Their results are protected by something stronger than an NDA: doctor–patient confidentiality. We’ll walk you through the full charts on a call — with their permission, not on a website.

§ 05 — Dosage & AdministrationSupply limited

Dosage: compounded
in small batches.

We cap our roster on purpose. Fewer accounts means senior operators on every one — no junior pods, no hand-offs, no filler. A limited number of intake slots open each quarter.

Apply for TreatmentQ3 2026 — 2 of 4 slots remaining
§ 06ContraindicationsDO NOT TAKE IF

Do not take May Cause Growth if:

  • 01you want a logo, not patients
  • 02you believe organic alone will save you
  • 03your offer isn’t ready for traffic
  • 04you are currently pregnant with another agency (finish the engagement first)
  • 05you are allergic to direct answers
§ 07New Patient IntakeFORM MCG-101
Form MCG-101 — six itemsUnder review within 2 business days

Begin intake.

Six items. Roughly two minutes. Spend, category, current setup, presenting condition, objective, and contact. A partner reads every submission personally — including the ones we decline.

Apply for TreatmentEmail doctor@maycausegrowth.com
  1. 01Monthly paid media spend
  2. 02Brand classification
  3. 03Channels currently running
  4. 04Presenting condition
  5. 05Six-month objective
  6. 06Prescriber contact details
Take as directed